Skip to main content
. Author manuscript; available in PMC: 2012 Jan 17.
Published in final edited form as: JAMA. 2010 Nov 3;304(17):1903–1911. doi: 10.1001/jama.2010.1510

Figure 1.

Figure 1

Flow of Patients in the Alzheimer’s Disease Cooperative Study (ADCS) Docosahexaenoic Acid Supplementation Trial

Study partner issue is included as a reason for discontinuation because of the requirement for a study partner to participate in several of the key outcome measures in this trial (eg, Clinical Dementia Rating sum of boxes, ADCS activities of daily living, and Neuropsychiatric Inventory). There were no significant differences in incidence of dropout, adverse events, or serious adverse events (Table 2).

aThere could be more than 1 reason for exclusion or study discontinuation.